OPKO Health to present new data on oral tablet treatment for obesity and metabolic disorders

From Yahoo Finance: 2025-06-29 03:03:00

OPKO Health, Inc. (NASDAQ: OPK) is among the top 10 healthcare penny stocks recommended by analysts. They will present new data on their investigational oral OPK-88006 tablet treatment at ENDO 2025, a major medical conference.

The drug OPK-88006 targets obesity, metabolic disorders, and fibrotic disorders. It is a novel dual agonist GLP-1/glucagon peptide developed for once-daily tablet treatment and weekly subcutaneous injection. The presentation at ENDO 2025 will showcase new data on the drug’s effects and profile.

Entera CEO Miranda Toledano emphasizes the rarity of oral peptides in metabolic therapy. The tablet and injectable formats could offer tailored regimens for patients with obesity, metabolic, and fibrotic disorders. The once-daily tablet aims to simplify dosing and improve tolerability for sustainable weight loss.

OPKO Health, Inc. is a diversified healthcare company focusing on pharmaceuticals, diagnostics, and multispecific antibody therapies for cancer, infectious diseases, and metabolic disorders. Key businesses include BioReference Health and ModeX Therapeutics, with a strong emphasis on next-generation immunotherapies.

While OPK presents investment potential, other AI stocks may offer greater upside potential and less downside risk. For those interested in undervalued AI stocks with benefits from Trump-era tariffs, consider exploring the best short-term AI stock and other investment opportunities.

For more insights on Goldman Sachs Energy Stocks and billionaire David Tepper’s top AI stock picks, visit the provided links. Disclosure: None.

Read more: OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025